4.3 Article

Suppressive effect of 1,4-anhydro-4-seleno-D-talitol (SeTal) on atopic dermatitis-like skin lesions in mice through regulation of inflammatory mediators

出版社

ELSEVIER GMBH
DOI: 10.1016/j.jtemb.2021.126795

关键词

Cytokine; Selenium; 4-Anhydro-4-seleno-D-talitol; Inflammation; Hydrocortisone

资金

  1. Seleno Therapeutics Pty. Ltd.
  2. CNPq [UNIVERSAL 429859/2018-0]
  3. FAPERGS [PqG 17/2551-0001013-2, PRONEM 16/2551-0000240-1]
  4. CAPES
  5. Independent Research Fund Denmark (Danmarks Frie Forskningsfond) [DFF-7014-00047]
  6. Novo Nordisk Foundation [NNF13OC0004294, NNF15OC0018300]
  7. CNPq
  8. Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) [001]

向作者/读者索取更多资源

Topical treatment with SeTal showed promising results in improving inflammatory markers, cutaneous severity scores, and scratching behavior in an atopic dermatitis mouse model, suggesting its therapeutic advantages for the treatment and control of AD.
Background: Atopic dermatitis (AD) is a multifactorial chronic inflammatory disease that affects similar to 20 % of children and 3% of adults globally and is generally treated by the topical application of steroidal drugs that have undesirable side-effects. The development of alternative therapies is therefore an important objective. The present study investigated the effects of topical treatment with a novel water-soluble selenium-containing carbohydrate derivative (4-anhydro-4-seleno-D-tatitol, SeTal) on the symptoms and inflammatory parameters in an AD mouse model. Methods: Mice were sensitized by applying 2,4-dinitrochlorobenzene (DNCB) to their dorsal skin on days 1-3, then further challenged on their ears and dorsal skin on days 14, 17, 20, 23, 26, and 29. SeTal (1 and 2%) or hydrocortisone (1%) was applied topically to the backs of the mice from days 14-29, and skin severity scores and scratching behavior determined on day 30. The mice were euthanized, and their ears and dorsal skin removed to quantify inflammatory parameters, edema, myeloperoxidase (MPO) activity, and AD-associated cytokines (tumor necrosis factor alpha (TNF-alpha), interleukins (IL)-18, and IL-33). Results: DNCB treatment induced skin lesions and increased the scratching behavior, ear edema, MPO activity (ear and dorsal skin), and cytokine levels in dorsal skin. Topical application of SeTal improved inflammatory markers (cytokine levels and MPO activity), cutaneous severity scores, and scratching behavior. Conclusion: The efficacy of SeTal was satisfactory in the analyzed parameters, showing similar or better results than hydrocortisone. SeTal appears to be therapeutically advantageous for the treatment and control of AD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据